Loading…
IN8bio, Inc. is projected to rise to $1.46 by 2027, a +1% move from its current price of $1.45. INAB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 6/10/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jun 11 | $1.39 | $1.45 | $1.51 | 0.00% |
| Jun 12 | $1.37 | $1.45 | $1.53 | 0.00% |
| Jun 13 | $1.36 | $1.45 | $1.55 | -0.01% |
| Jun 14 | $1.34 | $1.45 | $1.57 | -0.01% |
| Jun 15 | $1.33 | $1.45 | $1.58 | -0.01% |
| Jun 16 | $1.32 | $1.45 | $1.59 | -0.01% |
| Jun 17 | $1.31 | $1.45 | $1.61 | -0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.31 | $1.45 | $1.61 | -0.02% |
| Week 2 | $1.25 | $1.45 | $1.68 | -0.03% |
| Week 3 | $1.21 | $1.45 | $1.73 | -0.05% |
| Week 4 | $1.18 | $1.45 | $1.78 | -0.07% |
| Week 5 | $1.15 | $1.45 | $1.82 | -0.08% |
| Week 6 | $1.13 | $1.45 | $1.86 | -0.10% |
| Week 7 | $1.10 | $1.45 | $1.90 | -0.11% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.
Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc.
in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
IN8bio, Inc. (INAB) is a healthcare stock with a focus in the biotechnology sector. The stock trades at $1.45 per share and has a market cap of $13.91M, ranking 4,688 by market capitalization.
The year-by-year forecast suggests a gradual price uptick, with an average price rising from $1.45 in 2026 to $5.54 in 2050 and a max forecast of $12.02 in 2050. The implied ROI grows to 282.1% by 2050, with sentiment shifting from neutral to bullish across the longer horizon.
Among intermediate years, 2027 shows an average of $1.46 with a 0.5% ROI and neutral sentiment, while 2028–2035 show increasing averages and rising bullish momentum, including a 26.5% ROI in 2028 and a 52.8% ROI in 2035, culminating in strong long-term upside through 2050 (average $5.54, max $12.02).
A major floor 22.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.1% away) — a key level to hold.
The nearest ceiling, 29.0% above — a clean break opens room to run.
A major ceiling 42.1% above — clearing it would confirm fresh momentum.
Key INAB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INAB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.51 | Sell | $1.52 | Sell |
| MA 10 | $1.64 | Sell | $1.57 | Sell |
| MA 20 | $1.61 | Sell | $1.59 | Sell |
| MA 50 | $1.53 | Sell | $1.60 | Sell |
| MA 100 | $1.71 | Sell | $1.71 | Sell |
| MA 200 | $1.86 | Sell | $2.47 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.96 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -107.69 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -8.28 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.25 | Buy |
| Awesome (5,34) | -0.07 | Sell |
| Ultimate (7,14,28) | 29.30 | Buy |
| Momentum (10) | -0.23 | Sell |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 1.41 | Buy |
| ADX (14) | 15.40 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is bearish.
RSI14 is 40, indicating near-neutral to modestly bearish momentum. The stock trades below the SMA200 and just around the SMA50, with the SMA50 listed at $1.53 and the SMA200 at $1.86. Support sits at $1.42 and resistance at $1.87, suggesting a narrow trading setup near the current level.
The 30-day price range runs from a low of $1.11 to a high of $1.89, highlighting a tight, choppy move over the recent month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.35 | $1.45 | $1.91 | 0% | Neutral | |
| $1.12 | $1.46 | $2.06 | +1% | Neutral | |
| $1.34 | $1.83 | $2.70 | +26% | Bullish | |
| $1.43 | $2.02 | $3.10 | +40% | Bullish | |
| $1.35 | $1.96 | $3.10 | +35% | Bullish | |
| $1.30 | $1.95 | $3.17 | +35% | Bullish | |
| $1.22 | $1.88 | $3.14 | +30% | Bullish | |
| $1.20 | $1.90 | $3.23 | +31% | Bullish | |
| $1.15 | $1.87 | $3.24 | +29% | Bullish | |
| $1.33 | $2.21 | $3.91 | +52% | Bullish | |
| $1.33 | $2.45 | $4.69 | +69% | Bullish | |
| $2.48 | $5.52 | $11.80 | +281% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| June 2026 | $1.35 | $1.45 | $1.77 | +0.00% |
| July 2026 | $1.19 | $1.42 | $1.75 | -2.10% |
| August 2026 | $1.20 | $1.45 | $1.81 | +1.93% |
| September 2026 | $1.24 | $1.51 | $1.92 | +4.67% |
| October 2026 | $1.20 | $1.47 | $1.89 | -2.71% |
| November 2026 | $1.14 | $1.41 | $1.83 | -4.20% |
| December 2026 | $1.18 | $1.46 | $1.91 | +3.47% |
Click any year to see its month-by-month INAB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, INAB is projected to trade between $1.35 and $1.91, averaging $1.45 — a potential gain of 0% from today's $1.45. A consolidation phase looks the most probable path here.
IN8bio, Inc.'s 2027 outlook centres on $1.46, within a $1.12 to $2.06 range. That is up +1% on the projected 2026 average. That marks a +1% change versus current levels. Price action looks broadly range-bound.
By 2028, INAB could reach as high as $2.70, with a base case around $1.83 and support toward $1.34 — roughly +26% from $1.45. Buyers look set to stay in control over this stretch.
Expect INAB to range from $1.43 to $3.10 through 2029. The $2.02 average target implies a +40% move from current prices. That is up +11% on the projected 2028 average. Momentum favours further upside here.
The INAB price prediction for 2030 points to an average of $1.96 (low $1.35, high $3.10) — a potential gain of +35% on today's $1.45. Buyers look set to stay in control over this stretch.
In 2031, INAB is projected to trade between $1.30 and $3.17, averaging $1.95 — a potential gain of +35% from today's $1.45. That is -1% versus the projected 2030 average. Momentum favours further upside here.
IN8bio, Inc.'s 2032 outlook centres on $1.88, within a $1.22 to $3.14 range. That is -4% versus the projected 2031 average. That marks a +30% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, INAB could reach as high as $3.23, with a base case around $1.90 and support toward $1.20 — roughly +31% from $1.45. Momentum favours further upside here.
Expect INAB to range from $1.15 to $3.24 through 2034. The $1.87 average target implies a +29% move from current prices. That is -2% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The INAB price prediction for 2035 points to an average of $2.21 (low $1.33, high $3.91) — a potential gain of +52% on today's $1.45. Momentum favours further upside here.
In 2040, INAB is projected to trade between $1.33 and $4.69, averaging $2.45 — a potential gain of +69% from today's $1.45. That is up +11% on the projected 2035 average. Buyers look set to stay in control over this stretch.
IN8bio, Inc.'s 2050 outlook centres on $5.52, within a $2.48 to $11.80 range. That is up +125% on the projected 2040 average. That marks a +281% change versus current levels. Momentum favours further upside here.
Investing $1,000 in INAB today (≈ 689.655172 INAB) could be worth
$3,807.74
+$2,807.74 (+281%) by 2050 · US Dollar
Based on the average projected INAB price of $5.52 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INABwould be worth at today's price.
$1,000 invested in INAB on Jun 9, 2025 (≈ 324.675333 INAB) would be worth
$470.78
-$529.22 (-52.9%) today · 0.47× · US Dollar
Based on a INAB entry price of $3.08 vs. today's $1.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.73 | $838.15 | -16.2% |
| 1 month ago | $1.58 | $917.72 | -8.2% |
| 3 months ago | $1.81 | $801.1 | -19.9% |
| 6 months ago | $1.77 | $819.21 | -18.1% |
| 1 year ago | $3.08 | $470.78 | -52.9% |
| All time (4.9y) ago | $300 | $4.83 | -99.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INAB forecast.
Our base-case forecast reaches $2.90 around 2050.
Implied market cap at $2.90: $27.81M
The multi-year forecast depicts a bullish trajectory from the mid-to-late 2020s onward. In 2030, the average price is forecast at $1.96 with a range from $1.33 to $3.13 and an estimated ROI of 35.4%—a clear move higher within a longer bullish context. By 2040, the average rises to $2.44 with an ROI of 68.3% and a max near $4.73, reinforcing a sustained uptrend.
By 2050, the forecast envisions an average of $5.54 with a broad range from $2.49 to $12.02 and an extraordinary ROI of 282.1%, supported by a bullish sentiment throughout the long horizon. The earlier years (2026–2027) are neutral to modestly bearish, but the outlook strengthens into the late 2020s and into the 2030s–2050s, signaling meaningful upside potential despite inherent forecast uncertainty.
These figures are estimates and not guarantees. They illustrate a potential path for IN8bio, Inc. based on the provided projections, with higher conviction attached to the later years as sentiment shifts to bullish and price averages rise.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $1.96 with a range from $1.33 to $3.13, and an estimated ROI of 35.4%. The sentiment is listed as BULLISH.
The forecast projects growth with an average price of $1.45 in 2026 rising to $5.54 in 2050 and a 282.1% ROI in 2050, though early years show neutral to bearish signals. These are estimates, not guarantees.
Yes. The 2030 max forecast is $3.13, with later years also showing higher tops (2040 max $4.73; 2050 max $12.02). The 2030 average is $1.96.
The current price is $1.45 and the market cap is $13.91M.
The 2050 forecast shows an average price of $5.54 with a min of $2.49, a max of $12.02, and an ROI of 282.1%, with bullish sentiment.
IN8bio, Inc. Community Discussion
0Share your IN8bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.